Advertisements



Alexion to present results from ALXN1210 Phase 3 study at EHA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 14th, 2018

Calithera to present results from Phase 1 CB-839 combination study at ASCO

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 4th, 2018

Karyopharm to present Phase 2 SEAL study results at ASCO

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 16th, 2018

Cerus reports results of SPARC Phase 3 study at EHA meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 15th, 2018

Alnylam to present additional results from APOLLO study of patisiran at EAN

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 15th, 2018

Galmed up 60% to $11.30 after 52-week results from Phase 2b ARREST study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 12th, 2018

Galmed reports 52-week results from Phase 2b ARREST study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 12th, 2018

Pluristem reports "positive" results from Phase II clinical study of PLX-PAD

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 12th, 2018

More Data Needed On Proteostasis Therapeutics" Cystic Fibrosis Candidate, RBC Says In Downgrade

After Proteostasis Therapeutics Inc (NASDAQ: PTI)’s mixed Phase 2 results from a study of its PTI-801 cystic fibrosis transmembrane conductance regulator, RBC Latest Ratings for PTI DateF.....»»

Category: blogSource: benzingaJun 7th, 2018

Proteostasis announces "positive" results from Phase 1 Study of PTI-801

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 6th, 2018

Nightstar Therapeutics Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third Quarter 2018

Preliminary data from dose escalation study in the Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigm.....»»

Category: earningsSource: benzingaJun 6th, 2018

Deciphera reports updated interim phase 1 clinical study results with DCC-2618

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 3rd, 2018

Roche announced results from Phase III IMpower131 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 3rd, 2018

Celgene, bluebird bio report updated results of Phase I study of bb2121

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 1st, 2018

BioMarin updates results from Phase 1/2 study of valoctocogene roxaparvovec

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 22nd, 2018

Roche (RHHBY) Announces Positive Data on Hemophilia Drug

Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio. Roche RHHBY announced full results from the phase III study, HAVEN 3, evaluating haemo.....»»

Category: dealsSource: nytMay 21st, 2018

InflaRx N.V. Reports First Quarter 2018 Financial & Operating Results

Initiated international Phase IIb study of IFX-1 in Hidradenitis Suppurativa patients Completion of primary and secondary o.....»»

Category: earningsSource: benzingaMay 17th, 2018

Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatiti.....»»

Category: personnelSource: nytMay 16th, 2018

Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update

Interim Analysis for Phase 3 HONOR study of Tonmya® .....»»

Category: earningsSource: benzingaMay 14th, 2018

VBI Vaccines announces "positive" final Phase 1 study results for VBI-1501

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 10th, 2018

Why Karyopharm Is on the Move

Karyopharm Therapeutics saw its shares make a handy gain on Tuesday after the firm announced positive top-line results from the Phase 2b STORM study evaluating selinexor......»»

Category: blogSource: 247wallstMay 1st, 2018